Compare Coinbase Global, Inc. (COIN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Neurocrine Biosciences Inc — how do they compare? Coinbase Global, Inc. trades at $175.97 (market cap $45.38B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Coinbase Global, Inc. is far larger — about 3.2× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Neurocrine Biosciences Inc for 23 Days on average.
| COIN | NBIX | |
|---|---|---|
Market Cap | $45.38B | $14.36B |
Volume | 11,013,940 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $387.00 | $185.50 |
52-Week Low | $141.09 | $123.10 |
Typical Hold Time | 78 Days | 23 Days |
Enterprise Value | $43.03B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $178.45, down 3.92% with bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $7.18B in 2025 but negative net income margin of -15.72% and recent earnings misses. Analyst consensus remains positive with 55% buy ratings and $211.55 price target, while technical indicators show support at $177 and resistance at $180.
Outlook remains cautiously optimistic given analyst support and recent CFTC approval for derivatives expansion, but risks include volatile earnings performance, high valuation multiples, and regulatory uncertainty. The stock's current price near support levels presents potential entry point for long-term investors despite near-term headwinds.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
